Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 11, 2020 (6 years ago)

Carbamazepine Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Carbamazepine Tablets, USP 200 mg, packaged in a 500-count bottle, Rx only, Manufactured by: Torrent Pharmaceuticals Ltd, Bharuch 392130, India; Manufactured for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-268-05

Affected NDC 13668-0268-05

Compare with the code on your package — it is the most precise check available.

Drug: Carbamazepine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Carbamazepine
NDC 13668-0268
200 mg/1 Tablet
Oral
Torrent Pharmaceuticals Limited Rx
Recalling firm
Torrent Pharma Inc.
NDC code
13668-268-05
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1317-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Carbamazepine recalls

See all
Class II · Moderate risk

Carbamazepine Tablets

CGMP deviations: tablets with black specks.

Ongoing cGMP deviation Golden State Medical Supply Inc. NDC 51407-215-10 D-0771-2026
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026

Other recalls by Torrent Pharma Inc.

All 2020 recalls
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0456-2025
Class II · Moderate risk

Fluoxetine Tablets

CGMP Deviations: Presence of N-Nitroso Fluoxetine exceeding interim acceptable intake limit.

Completed Nitrosamine impurity Torrent Pharma Inc. D-0455-2025